Yuanda Pharmaceutical regards interventional oncology produc...
Yuanda Pharmaceutical regards interventional oncology products as the company's strategic focus. LavATM was successfully listed in the US, providing a new direction for the expansion of the indications for Yigantaytrium [90Y] microspherical injection. The company will increase investment in research and development of anti-tumor nuclear drugs and promote collaboration between products under development and products currently on sale.
Yuanda Pharmaceutical (00512), an innovative liquid embolizer, is officially commercialized in the US, providing a new treatment for peripheral arterial hemorrhage
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment